RNS Number : 5906C
CT Private Equity Trust PLC
28 March 2025
 

To: Stock Exchange

Date: 28 March 2025




 

 

CT Private Equity Trust PLC

LEI: 2138009FW98WZFCGRN66

Preliminary Announcement for the Year Ended 31 December 2024
 

CT Private Equity Trust PLC today announces its unaudited financial results for the year ended 31 December 2024.

 

Financial Highlights

 

·    Share price total return for the year of 10.9 per cent for the Ordinary Shares.*

 

·     NAV of 706.03 pence per Ordinary Share reflecting a total return for the year of 4.6 per cent.*

 

·     Total quarterly dividends for the year of 28.04 pence per Ordinary Share.  Quarterly dividend of 7.01 pence per Ordinary Share to be paid on 30 April 2025.

 

·     Dividend yield of 5.7 per cent based on the year-end share price.*  £146 million of dividends returned to Shareholders since January 2013.  This represents a ten-year compound annual growth rate of 10.0%.

 

·      Realisations for 2024 of £108.6 million, an increase of 76% in comparison to 2023.

 

·     As at 31 December 2024 net debt was £76.5 million equivalent to a gearing level of 13.2%.

 

·     The Company enters 2025 with a strong balance sheet and a well-diversified portfolio of high growth and dynamic companies.

 

 

 

*see Alternative Performance Measures

 

Chairman's Statement

 

Fellow Shareholders,

 

This report is for the year ended 31 December 2024.  The NAV per share at the year-end was 706.03p (2023: 702.50p).  Taking account of the dividends received by Shareholders during this year your Company achieved a net asset value ("NAV") total return of 4.6 per cent (2023: 2.8 per cent).

 

The share price at the year-end was 488.00p per share (2023: 468.00p).  The share price total return for the year was 10.9 per cent (2023: 17.6 per cent).  This compares to a total return from the FTSE All-Share Index for 2024 of 9.5 per cent (2023: 7.9 per cent).

 

The share price discount as at 31 December 2024 was 30.9 per cent (2023: 33.4%)*. 

 

During the year the Company made new investments, either through funds or as co-investments, totalling £58.7 million. Realisations and associated income totalled £108.6 million. Outstanding undrawn commitments at the year-end were £193.0 million of which £27.0 million was to funds where the investment period had expired.

 

Approximately 91 per cent of the valuation by value is based on 31 December 2024 valuations and 9 per cent on September 2024 valuations.

 

The Company's performance fee arrangements contain a hurdle rate, calculated over rolling three-year periods, of an IRR of 8.0 per cent per annum. The annual IRR of the NAV for the three-year period ended 31 December 2024 was 7.7 per cent and, consequently, a performance fee is not payable to the Manager, in respect of 2024.

 

Capital Allocation

 

Since its foundation, the Company has been both innovative and proactive with regard to its capital strategy. The Board regularly reviews the Company's capital allocation and seeks to balance the benefits of an immediate enhancement to NAV from share buybacks against the anticipated longer-term returns from new investment.

 

Dividends

 

The Company's innovative dividend policy was introduced in 2012 and remains the cornerstone of the Company's capital allocation strategy. The Company pays a substantial dividend from realised profits allowing Shareholders to participate, to some degree, directly in the proceeds of the steady stream of private equity realisations which the Company achieves. Since 1 January 2013 the Company has returned £146 million of dividends to Shareholders. This represents a ten-year compound annual growth rate of 10.0 per cent. This policy provides for a steadily growing dividend with downside protection. Your Board is fully committed to maintaining this approach for the foreseeable future.

 

The Company's quarterly dividends are payable in respect of the quarters ended 31 March, 30 June, 30 September and 31 December and are paid in the following July, October, January and April respectively. As Shareholders do not have an opportunity to approve a final dividend at each Annual General Meeting, Shareholders are asked to approve the Company's dividend policy at the forthcoming Annual General Meeting.

 

In accordance with the Company's stated dividend policy, the Board recommends a further quarterly dividend of 7.01 pence per Ordinary Share, payable on 30 April 2025 to Shareholders on the register on 11 April 2025 and an ex-dividend date of 10 April 2025. Total dividends paid for the year therefore amount to 28.04 pence per Ordinary Share equivalent to a dividend yield of 5.7 per cent at the year-end.

 

Share Buybacks

 

The Company does not have a stated discount management policy. However, the Board recognises the importance of movements in the Company's discount upon the return that Shareholders receive and monitors closely the discount's absolute and relative levels. At the Annual General Meeting held on 29 May 2024, the Board sought and received from Shareholders the authority to buy back up to 14.99% of the Company's share capital. Buybacks can only be made at a cost per share which is below the prevailing NAV.

 

During the year ended 31 December 2024 the Company bought back, to be held in treasury, a total of 1.25 million shares. This equated to 1.7% of the shares in issue, excluding those held in treasury, at 31 December 2023. The shares were bought back in two tranches at 460 pence per share and cost, in total, £5.8 million.

 

These shares are held in treasury to allow the Company to re-issue them quickly and cost effectively. At last year's AGM the Board sought and received the authority from Shareholders to re-issue treasury shares or issue new shares, subject to limitations on the number and price. Treasury shares can only be re-issued and new shares issued at a price which would not dilute the NAV of existing Shareholders.

 

The Board seeks renewal of these buyback and reissuance authorities at the AGM to be held on 29 May 2025.

 

The Company continues to appraise the relative merits of using capital for share buybacks versus new investment whilst protecting and growing the dividend.

 

Financing

 

To reflect the growth in the size of the Company during February 2024, the Company entered into a revised loan agreement with RBSI and State Street. 

 

The revised loan agreement increased the €25 million term loan with RBSI to €60 million and retained the revolving credit facility with RBSI and State Street at £95 million.  The term of the agreement, which was due to expire in June 2024, was extended to February 2027.

 

The Company had net debt at 31 December 2024 of £76.5 million (31 December 2023: £87.2 million). This represents gearing of 13.2% (31 December 2023: 14.6%). Approximately half of the Company's borrowing facilities are unused with plenty of headroom.

 

Annual General Meeting

 

The Annual General Meeting ("AGM") will be held at 13.00 on 29 May 2025 at the offices of Columbia Threadneedle Investments, Cannon Place, Cannon Street, London EC4N 6AG. This will be followed by a presentation by Hamish Mair, the Company's Investment Manager on the Company and its investment portfolio.

 

For Shareholders who are unable to attend the meeting, any questions they may have regarding the resolutions proposed at the AGM or the performance of the Company can be directed to a dedicated email account, petagm@columbiathreadneedle.com, by Thursday 22 May 2025. The Board will endeavour to ensure that questions received by such date will be addressed at the meeting.  The meeting will be recorded and will be available to view on the Company's website, ctprivateequitytrust.com, shortly thereafter.

 

In addition, the AGM and Investment Manager presentation will be broadcast live on the Investor Meet Company platform. This broadcast is open to all existing and potential Shareholders to view. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am on 28 May 2025. Investors can sign up to Investor Meet Company for free and add to meet CT Private Equity Trust plc via www.investormeetcompany.com/ct-private-equity-trust-plc/register-investor. Investors who already follow CT Private Equity Trust plc on the Investor Meet Company platform will automatically be invited.

 

All Shareholders that cannot attend in person are encouraged to complete and submit their Form of Proxy or Form of Direction in advance of the meeting to ensure that their votes will count.

 

Review and Outlook

 

We have experienced significant  changes over the last five years. Post pandemic markets are significantly more volatile. Across the developed world public debt is at record levels, a legacy of the pandemic and the earlier period of ultra-low interest rates. According to the Institute of International Finance global debt reached a record high of $318 trillion in 2024. The debt burden has been further increased by a normalisation of interest rates, further stretching public budgets many of which were already challenged by aging populations and climate change. Geopolitical risks have also increased significantly, with Russia's invasion of Ukraine, war in the Middle East, an increasingly assertive China and a significant shift in US foreign policy. Meanwhile listed markets have become increasingly concentrated, in a few very large US technology stocks (at the end of 2024 the 'magnificent seven', Nvidia, Apple, Amazon, Alphabet, Meta, Microsoft and Tesla, accounted for nearly a quarter of the MSCI World index) increasing systemic risk.

 

As described in the Investment Manager's Review your Company's portfolio has coped exceptionally well with these challenges, providing Shareholders with both capital growth and income while mitigating risk through strong diversification. Over the last five years your Company has delivered an impressive NAV total return of 105.9%. The Company's  long term track record was recognised by The Association of Investment Companies ("the AIC"), which named CT Private Equity Trust PLC as the ninth best performing investment trust over the last ten years in February 2025. Having paid a steadily increasing dividend for over 12 years the Company is also recognised as an AIC Next Generation Dividend Hero. To qualify an investment trust requires sustained growth in annual dividends for ten years. This combination of strong growth and income yield puts your CT Private Equity Trust PLC in rare company. 

 

This excellent performance is based on the strength of the underlying fundamentals for our investee companies which, supported by our investment partners, have adapted to changing environments and recorded impressive growth in revenues and profits. Meanwhile the flow of investment opportunities that your managers appraise remains very strong reflecting the breadth of the mid-market universe we address and the depth of our networks in these markets internationally. The outlook for 2025 remains uncertain, however your Company remains well positioned to deliver further gains to Shareholders whilst laying the foundations for future growth.

Richard Gray

Chairman

 

*see Alternative Performance Measures

 

 


Investment Manager's Review

 

Introduction

2024 has seen the private equity market stabilise after what has been the most challenging period for the industry since the great financial crisis. During the year interest rates and inflation finally reduced and economic growth in many of our key markets stabilised. As a result, investment and exit activity began to recover after two years of decline. According to Bain & Company global buyout investment and exit value increased 37% and 34% respectively in 2024.

This increased activity can be seen in the increase in realisations received by the Company during the year, which totalled £108.6 million, up 76% on the prior year. Markets however remain uncertain and shifting, and a full recovery is yet to take hold.

New Investments

Dealflow for new funds and co-investments remains very strong, with hundreds of investment opportunities reviewed over the year. These come from both long-term investment partners and others who are newer to our network.

The total invested in funds and co-investments in the year was £58.7 million, down from £110.8 million in 2023. We remain highly selective in light of the continued challenges in exit markets.

Five new fund commitments were made in the year. £10.0 million was committed to August Equity VI, the latest in a series of commitments to this accomplished lower mid-market UK buyout specialist.

£5.0 million was committed to Inflexion Enterprise Fund VI, the latest in a series of Inflexion funds focusing on lower mid-market buyouts in the UK and Northern Europe.

£6.0 million was committed to Corran Environmental Fund II, a UK lower mid-market growth fund with a focus on clean energy and environmental companies. The fund's cornerstone investment Vital Energi is the UK's leading district heating and energy efficiency specialist which also owns and operates an energy-from-waste plant at Drakelow, Derbyshire.

€5.0 million was committed to the Agilitas Human Investment Fund a pan-European fund with an explicit investment objective of helping people that are disadvantaged or in need. We have invested with Agilitas both through funds and co-investments several times over the years.

€4.0 million has been committed to ARCHIMED MED Rise. ARCHIMED is a leading France headquartered healthcare specialist with whom we have invested several times. This fund targets buyouts of small healthcare businesses operating within attractive niches globally.

There was one new co-investment plus several significant follow-on investments primarily to fund add-on acquisitions.

A total of £4.0 million was invested in Accounts IQ, a B2B cloud-based accounting software provider for mid-sized companies in the UK and Ireland. The investment is led by Axiom I, the enterprise software focussed lower mid-market fund, which drew £1.4 million for the investment, alongside which we co-invested a further £2.6 million.

£4.2 million was invested in Breeze Group, the parent company of Contained Air Solutions (the Manchester-based manufacturer of microbiological safety cabinets) to fund complementary acquisitions. Amercare is a UK-based designer and supplier of isolators for medical and pharmaceutical applications, including cell therapy and radiopharmacy. BioSpherix is a US-based provider of novel cleanroom grade containment solutions aimed at the cell therapy market. Its products control the environmental conditions to optimise cell health and reproducibility.

£2.2 million was invested in MedSpa, the Canada-based chain of aesthetics clinics to finance three acquisitions. £1.6 million was invested in Texas based digital payment solutions provider Aurora Payment Solutions. £1.0 million was invested in Utimaco, the German encryption and cybersecurity solutions provider. £0.7 million of additional working capital was invested in the US focussed Mexican restaurant chain Rosa Mexicano. £0.5 million was invested in Polaris Software, the UK based provider of compliance software to police and local authorities. £0.5 million was invested in GT Medical, the developer of the brain cancer radiotherapy device GammaTile.

The funds in our portfolio have made several new investments which cover various sectors and geographies. Below is a selection of the more material.

In the UK Corran Environmental II called £3.7 million for investment in district heating and environmental efficiency specialist Vital Energi. SEP VI invested £0.7 million in Braincube, the French industrial internet of things software company which specialises in optimising manufacturing processes, and £0.9 million in Cora, an Irish software company specialising in project management software for the aerospace, defence, healthcare and life sciences sectors. Kester Capital III called £1.2 million for an investment in The Boundary, a creative agency providing computer generated imagery and marketing materials to the global real estate industry and £0.5 million for GXP Exchange, a leading provider of clinical/pharmacovigilance audit and related consulting services to the pharmaceutical and biotech sectors. FPE III called £0.8 million for an investment in Clearstate, a leading provider of market data to the MedTech sector, which is a carve out from The Economist Group, and £1.0 million for Vanda Research, a provider of specialist research and data products for hedge funds and investment banks. Piper Private Equity VII invested £0.7 million in Inside Travel Group, a leading Asia-focused 'cultural adventure' travel brand.

In Europe Corsair VI, the financial services specialists, called £1.1 million for MJM, a leading independent commercial insurance broker in Poland. Also in Poland, Avallon III called £0.6 million for MPPK, a pet food company. Vaaka IV called £0.9 million to invest in Finnish IT infrastructure provider Tietokeskus alongside a continuation vehicle. We had existing exposure to this business through the commitment to Vaaka II. In Italy, Wisequity VI called £1.1 million for Serbios a leading Italian bio-controls company (providing biological alternatives to pesticides and agrochemicals). This is the first acquisition within Greenexta, a newly established buy-and-build platform for natural solutions for agriculture. Wisequity VI also called £0.6 million for Case Della Piada, a leading Italian producer of flatbreads. Inflexion Buyout Fund VI called £1.6 million for two European investments. DSS+ (£0.8 million) is a Swiss health and safety focussed management consultancy and Nomentia (£0.7 million), a Finland-based cash and treasury management software provider. Hg Saturn 3 called £0.5 million for GGW, a European insurance brokerage platform for SMEs in Germany's Mittelstand. Corpfin V invested £0.5 million in Groupo Versus, which provides training and education for military police, national police and prison officers in Spain.

In North America Procuritas VII called £0.4 million for Precision Biologic, a Canadian supplier of high-quality reagents used for haemostasis (blood coagulation) diagnostics serving a mainly North American customer base of over a thousand laboratories, hospitals, universities and research centres. MidOcean VI invested £0.4 million in SI Solutions a US provider of engineering, testing, compliance and maintenance services for power and critical infrastructure markets. Corsair VI called a further £0.6 million for a follow-on investment in HungerRush (restaurant point-of-sale software) as part of a debt restructuring to increase flexibility on its financial covenants and lower debt service costs. Graycliff IV invested £0.5 million in Diamond Chemical, a manufacturer of cleaning and sanitation chemicals serving hospitality, food service, commercial laundry, and other end markets.

Realisations

After a strong recovery in the second and third quarter realisations slowed in the final quarter of the year. The total for the year was £108.6 million, up 76% on the £61.7 million achieved in 2023.

There were three co-investments realised in the year. In April Kester Capital sold large format pet retailer Jollyes to TDR Capital returning £18.6 million (4.2x cost and 27% IRR). The company doubled EBITDA and built its chain from 64 stores to 100 during the hold period.

In May Buckthorn Partners sold Aberdeen-based oil and gas wellbore plug and abandonment specialist Coretrax to large, listed energy services group Expro returning £13.9 million (1.7x cost and 11% IRR). A reasonable result given the volatility in energy markets since the investment was made in 2018.

Finally in August Kester Capital sold ATEC to Perwyn. The combined proceeds from both the co-investment, the proportion held in the GCP Europe II fund and the proportion held through The Aurora Fund position was £18.5 million. ATEC is a specialist insurance broker and general manager for niche areas such as caravans, beach huts and boats. It has grown profits almost fourfold during the holding period and significantly expanded its product offering.

There was also a steady flow of excellent exits from within our fund investments. In the UK August Equity IV returned £3.5 million through the sale of Agilio, the healthcare compliance software company, achieving an exceptional return of 9.2x cost and an IRR of 72%. Apiary exited TAG, the leading travel management company servicing the global live music and entertainment industry, which was hard hit by the Covid pandemic, returning £1.5 million (4.0x cost and 29% IRR). RJD Fund III exited veterinary education company Improve International returning £1.4 million (3.3x cost and 49% IRR). Inflexion Enterprise Fund IV sold ATG, a global automative data and software company, returning £0.9 million, an impressive 6.8x cost and 39% IRR over the five-year hold and pet supplements company Lintbells realising £1.0 million (5.5x cost and an IRR of 34%). Inflexion Enterprise Fund V returned £1.2 million from the sale of commercial insurance broker DR&P for an excellent 11.2x cost and 77% IRR.

In the Netherlands Bencis V had an exceptional year, returning £6.6 million from a series of excellent exits. It returned £1.9 million  (7.2x cost and 49% IRR) from the sale of Vecos, a cloud-based locker management system provider; £1.9 million (13.9x cost and 61% IRR) from the sale of Kooi, a mobile security systems provider; £1.1 million (7.2x cost and 35% IRR) from the sale of Tech Tribes, a digital transformation consultancy company; £0.9 million (4.7x cost and 36% IRR) from the sale of Ceban Pharmaceuticals, a business which specialises in compounding drugs in different formats and owns a major pharmacy chain Medsen; and £0.9 million (7.5x cost and 33% IRR) from the sale of Olyslager, a supplier of lubricant data for companies in the oil industry.

In the Nordics Summa II sold Olink to Thermo Fisher returning £3.6 million (9.9x cost and an IRR of 67%). Olink has developed a technology for analysing proteins which is used in human protein biomarker research. Meanwhile Summa I returned £1.7 million (5.6x cost and 31% IRR) through the sale of Pagero, a procure to pay software as a service company, to Thomson Reuters.

In France, Montefiore IV returned £3.1 million. £2.5 million was returned from the sale of EDG (digital services for French companies) and Groupe Premium (life and pension insurance broker) to a continuation vehicle and £0.5 million (2.9x cost and 21% IRR) was returned from Cruiseline, the online travel agent for cruises; this follows the successful resolution of a long running legal case after Abénex Capital pulled out of the agreed purchase of the business at the onset of the Covid pandemic. Chequers Capital XVII also returned £1.5 million (3.6x cost) from the sale of Somacis, a designer and manufacturer of high mix, low volume printed circuit boards.

Italian fund Nem Impresse made its final exit with the sale of business processing and outsourcing company Kauri yielding £2.1 million. Also in continental Europe, DBAG VIII returned £1.7 million (3.2x cost and 63% IRR) from the sale of in-tech a provider of software development, testing and validation.

In the US Graycliff continued its excellent run of exits returning £7.5 million in the year from fund III and IV. The sale of EMC, a switches and transformers manufacturer, achieved another exceptional outcome and returned £2.5 million (8.2x cost and an IRR of 146%); sweeteners manufacturer Ingredients Plus returned £2.1 million (3.3x cost, 34% IRR); the sale of Landmark Structures, elevated water towers, returned £1.9 million (7.8x cost and 132% IRR); and Ballymore, the designer and manufacturer of safety material handling equipment, returned £1.1 million (4.0x cost and 60% IRR).

Valuation Movements

Valuations were broadly flat in the first three quarters of the year, before increasing in the final quarter. Over the full year the portfolio was up £37.6 million (6.2%) before foreign exchange movements (-1.5%) and £28.4 million (4.7%) after FX.

The largest uplift was +£5.9 million for ATEC, the specialist insurer, which Kester sold in August to private equity house Perwyn. This was followed by an uplift of +£5.8 million in British lifestyle clothing and accessories retailer Weird Fish, which continues to perform very strongly under new CEO David Butler and recorded record profits in 2024. Inflexion Strategic Partners is up £4.6 million, reflecting impressive growth in assets under management. Other notable uplifts in the co-investment portfolio include encryption and cybersecurity solutions provider Utimaco (+£2.9 million); Denmark-based care company Habitus (+£2.4 million); social housing repairs and maintenance provider CARDO Group (+£2.0 million).

Within the funds portfolio uplifts include Axiom I (+£1.7 million), Inflexion Supplemental Fund V (+£1.7 million), Bencis V (+£1.5 million) due to the previously mentioned strong realisations and FPE II (+£1.5 million) due to several uplifts across the portfolio.

Write-downs were dominated by companies that have experienced a negative long-term impact from the Covid pandemic. Some consumer businesses experienced very rapid growth during the pandemic, which has since moderated due to reduced consumer confidence, changing priorities, or because orders were pulled forward by the pandemic and lockdowns. As previously reported Leader, the electric bike company in Bulgaria, is operating in a challenging market due to reduced consumer demand. The sector is expected to return to growth, however only after a serious destocking phase which is affecting the whole industry. The valuation is down by £2.4 million. Omlet, the premium pet products brand, continues to experience difficult trading conditions and weaker consumer demand and was down £2.0 million. Rosa Mexicano, the Mexican restaurant chain, has experienced weaker trading and is down by £1.6 million. In all cases management has been strengthened, turnaround plans are in place, and we are seeing encouraging signs of recovery.

Meanwhile changes to working practices have impacted companies such as Muraflex, which provides office renovations in North America, leading to a £2.6 million write-down in Aliante 3 and Agilico, which provides printers and scanners to offices, which is down £2.1 million.

Financing

During the year there was a net inflow of £49.9 million from the portfolio, as realisations of £108.6 million exceeded investments of £58.7 million. At the end of 2024 the net debt of the Company was £76.5 million which was comfortably within the limits of the borrowing capacity and represented gearing of 13.2%.

As previously reported, in April the Company bought back 1.25 million shares at 460p which amounted to 1.7% of the issued share capital, excluding shares held in treasury, at a cost of £5.8 million. The Company continues to appraise the relative merits of using capital for share buy-backs versus new investment whilst protecting and growing the dividend.

Outlook

2024 saw a good recovery in realisations, with the Company receiving £108.6 million in the year, an increase of 76% on 2023, representing significant positive cashflow for the Company. This is only the third year in the Company's history that annual realisations have exceeded £100 million (though this is largely due to the strong growth of the Company). Realisations during the year were 18% of opening portfolio value, a good uplift on the prior year, but still below the 10-year average of 25%. Further growth in realisations and liquidity are essential for the continued recovery of the private equity market (and in particular fundraising) and are a strong focus for private equity managers. As exits are typically at a significant premium to holding value an uptick in realisations should also feed through into strong returns.

Most of the conditions required for a recovery in 2025 appear to be in place. Interest rates and inflation have moderated and are expected to decrease further in many markets, debt availability and pricing has improved, and there is plenty of capital in private equity funds that managers are keen to invest. The key to building the recovery's momentum is business and investor confidence. This is threatened by persistent uncertainty: geopolitical tensions are high, wars continue in the Middle East and Ukraine, new trade wars threaten, and radical changes to US foreign policy require countries across the globe to adapt. There are likely to be significant changes in 2025. While this presents risk it also provides significant opportunities for those able to adjust and to act with confidence.

As the most engaged and aligned of asset classes, private equity is uniquely positioned to rapidly adapt to changing environments, with private equity managers and company management able to work together to deliver transformational change and deliver growth. The Company has consistently demonstrated its ability to outperform in uncertain times and to deliver a strong and growing dividend. We enter 2025, with a strong balance sheet and a well-diversified portfolio of high growth and dynamic companies.

 

 

 

Hamish Mair

Investment Manager

CT Investment Business Limited

Portfolio Summary

Portfolio Distribution at 31 December 2024

% of Total

31 December 2024

% of Total

31 December 2023

Buyout Funds - Pan European*

11.6

10.5

Buyout Funds - UK

19.2

16.2

Buyout Funds - Continental Europe†

15.5

18.2

Secondary Funds

-

0.1

Private Equity Funds - USA

4.4

5.0

Private Equity Funds - Global

2.7

1.7

Venture Capital Funds

4.5

3.7

Direct Investments/Co-investments

42.1

44.6


100.0

100.0

* Europe including the UK.

† Europe excluding the UK.



 

 

 

 

 

 

 

 

Ten Largest Holdings

As at 31 December 2024

Total Valuation £'000

% of Total Portfolio

Inflexion Strategic Partners

19,296

3.3

Sigma

16,031

2.7

Weird Fish

15,118

2.6

August Equity Partners V

12,096

2.1

TWMA

12,087

2.1

Utimaco

10,661

1.8

San Siro

10,460

1.8

Aurora Payment Solutions

9,996

1.7

Stirling Square Capital II

9,554

1.6

Inflexion Supplemental V

9,459

1.6

124,758

21.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Portfolio Holdings

 

Investment

Geographic Focus

 

Total

Valuation

£'000

% of Total Portfolio

 

Buyout Funds - Pan European




 

Stirling Square Capital II

Europe

9,554

1.6

 

Apposite Healthcare III

Europe

9,321

1.6

 

F&C European Capital Partners

Europe

8,867

1.5

 

Apposite Healthcare II

Europe

8,248

1.4

 

Summa III

Northern Europe

3,269

0.6

 

MED II

Western Europe

3,060

0.5

 

Agilitas 2015 Fund

Northern Europe

3,037

0.5

 

Verdane XI

Northern Europe

2,941

0.5

 

Wisequity VI

Italy

2,910

0.5

 

Magnesium Capital 1

Europe

2,430

0.4

 

Astorg VI

Western Europe

2,239

0.4

 

Volpi III

Northern Europe

2,104

0.4

 

MED Platform II

Global

2,068

0.3

 

KKA II

Europe

1,573

0.3

 

ARCHIMED MED III

Global

1,452

0.3

 

Agilitas 2020 Fund

Europe

1,228

0.2

 

Verdane Edda III

Northern Europe

1,059

0.2

 

TDR Capital II

Western Europe

903

0.2

 

TDR II Annex Fund

Western Europe

791

0.1

 

Inflexion Partnership III

Europe

526

0.1

 

Agilitas 2024 HIF

Europe

69

-

 

Total Buyout Funds - Pan European


67,649

11.6

 

 

Buyout Funds - UK




 

Inflexion Strategic Partners

United Kingdom

19,296

3.3

 

August Equity Partners V

United Kingdom

12,096

2.1

 

Inflexion Supplemental V

United Kingdom

9,459

1.6

 

Inflexion Buyout Fund V

United Kingdom

6,795

1.2

 

Apiary Capital Partners I

United Kingdom

6,450

1.1

 

Inflexion Buyout Fund VI

United Kingdom

5,217

0.9

 

FPE Fund III

United Kingdom

5,006

0.9

 

Axiom 1

United Kingdom

4,983

0.8

 

FPE Fund II

United Kingdom

4,866

0.8

 

August Equity Partners IV

United Kingdom

4,497

0.8

 

Kester Capital II

United Kingdom

4,468

0.8

 

Corran Environmental II

United Kingdom

4,207

0.7

 

Inflexion Partnership Capital II

United Kingdom

3,974

0.7

 

Piper Private Equity VI

United Kingdom

3,884

0.7

 

Piper Private Equity VII

United Kingdom

3,266

0.6

 

Kester Capital III

United Kingdom

2,372

0.4

 

Inflexion Buyout Fund IV

United Kingdom

2,225

0.4

 

Inflexion Enterprise Fund V

United Kingdom

2,116

0.4

 

Inflexion Supplemental IV

United Kingdom

1,449

0.2

 

Inflexion Enterprise Fund IV

United Kingdom

1,444

0.2

 

Primary Capital IV

United Kingdom

1,440

0.2

 

Inflexion Partnership Capital I

United Kingdom

1,266

0.2

 

RJD Private Equity Fund III

United Kingdom

467

0.1

 

Horizon Capital 2013

United Kingdom

377

0.1

 

GCP Europe II

United Kingdom

201

-

 

Piper Private Equity V

United Kingdom

163

-

 

August Equity Partners VI

United Kingdom

111

-

 

Dunedin Buyout Fund II

United Kingdom

5

-

 

Total Buyout Funds - UK


112,100

 



 

 

 

 





 





 

Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

 

Buyout Funds - Continental Europe




 

Aliante Equity 3

Italy

8,366

1.4

 

Avallon MBO Fund III

Poland

6,352

1.1

 

Vaaka III

Finland

5,828

1.0

 

DBAG VII

DACH

5,714

1.0

 

Bencis V

Benelux

5,232

0.9

 

Capvis III CV

DACH

4,654

0.8

 

Montefiore V

France

4,252

0.7

 

Verdane Edda

Nordic

4,224

0.7

 

DBAG VIII

DACH

4,113

0.7

 

Corpfin V

Spain

4,086

0.7

 

Procuritas VII

Nordic

3,827

0.7

 

Procuritas VI

Nordic

3,728

0.6

 

Chequers Capital XVII

France

3,675

0.6

 

ARX CEE IV

Eastern Europe

3,003

0.5

 

Procuritas Capital IV

Nordic

2,564

0.4

 

Italian Portfolio

Italy

2,487

0.4

 

Vaaka IV

Finland

2,335

0.4

 

Montefiore IV

France

2,042

0.4

 

Aurica IV

Spain

1,936

0.3

 

Capvis IV

DACH

1,794

0.3

 

Corpfin Capital Fund IV

Spain

1,591

0.3

 

Summa II

Nordic

1,417

0.3

 

Summa I

Nordic

1,396

0.2

 

DBAG VIIB

DACH

1,036

0.2

 

Portobello Fund III

Spain

1,007

0.2

 

DBAG VIIIB

DACH

946

0.2

 

DBAG Fund VI

DACH

828

0.2

 

Chequers Capital XVI

France

621

0.1

 

Vaaka II

Finland

374

0.1

 

Ciclad 5

France

295

0.1

 

PineBridge New Europe II

Eastern Europe

246

-

 

Gilde Buyout Fund III

Benelux

88

-

 

Procuritas Capital V

Nordic

71

-

 

Capvis III

DACH

50

-

 

Montefiore Expansion

France

47

-

 

DBAG Fund V

DACH

5

-

 

Total Buyout Funds - Continental Europe


90,230

15.5

 





 





 

 

 




 





Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

 










Private Equity Funds - USA

Blue Point Capital IV

North America

7,475

1.3

Level 5 Fund II

United States

3,296

0.6

Camden Partners IV

United States

3,218

0.5

Purpose Brands (Level 5)

United States

3,104

0.5

MidOcean VI

United States

2,257

0.4

Blue Point Capital III

North America

2,065

0.3

Stellex Capital Partners

North America

1,729

0.3

Graycliff IV

North America

1,601

0.3

Graycliff III

United States

1,061

0.2

Blue Point Capital II

North America

162

-

Total Private Equity Funds - USA


25,968

4.4

 




 




Private Equity Funds - Global




Corsair VI

Global

8,424

1.4

Hg Saturn 3

Global

4,951

0.9

Hg Mercury 4

Global

897

0.2

PineBridge GEM II

Global

654

0.1

F&C Climate Opportunity Partners

Global

421

0.1

AIF Capital Asia III

Asia

111

-

PineBridge Latin America II

South America

59

-

Warburg Pincus IX

Global

10

-

Total Private Equity Funds - Global


15,527

2.7

 

 

Venture Capital Funds




SEP V

Global

9,383

1.6

MVM V

Global

4,413

0.8

SEP VI

Europe

3,140

0.5

MVM VI

Global

2,950

0.5

Kurma Biofund II

Europe

2,735

0.5

Northern Gritstone

United Kingdom

1,697

0.3

SEP IV

United Kingdom

1,190

0.2

Pentech Fund II

United Kingdom

377

0.1

SEP II

United Kingdom

260

-

SEP III

United Kingdom

60

-

Environmental Technologies Fund

Europe

57

-

Life Sciences Partners III

Western Europe

31

-

Total Venture Capital Funds


26,293

4.5

 

 

Secondary Funds




The Aurora Fund

Europe

205

-

Total Secondary Funds


205

-

 

 

 

 

 

 

 

 

 

 

Investment

Geographic Focus

 

Total

Valuation £'000

% of Total Portfolio

Direct Investments/Co-investments




Sigma

United States

16,031

2.7

Weird Fish

United Kingdom

15,118

2.6

TWMA

United Kingdom

12,087

2.1

Utimaco

DACH

10,661

1.8

San Siro

Italy

10,460

1.8

Aurora Payment Solutions

United States

9,996

1.7

Amethyst Radiotherapy

Europe

8,786

1.5

Breeze Group (CAS)

United Kingdom

7,998

1.4

Cyclomedia

Netherlands

7,828

1.3

Asbury Carbons

North America

7,342

1.3

CARDO Group

United Kingdom

6,955

1.2

Velos IoT (JT IoT)

United Kingdom

6,853

1.2

Prollenium

North America

6,608

1.1

Swanton

United Kingdom

6,589

1.1

Habitus

Denmark

6,395

1.1

Orbis

United Kingdom

6,282

1.1

Family First

United Kingdom

6,113

1.1

Cyberhawk

United Kingdom

5,987

1.0

Rosa Mexicano

United States

5,902

1.0

Polaris Software (StarTraq)

United Kingdom

5,806

1.0

123Dentist

Canada

4,878

0.8

Cybit (Perfect Image)

United Kingdom

4,874

0.8

Braincube

France

4,652

0.8

MedSpa Partners

Canada

4,632

0.8

LeadVenture

United States

4,510

0.8

AccuVein

United States

4,273

0.7

Walkers Transport

United Kingdom

4,172

0.7

1Med

Switzerland

4,163

0.7

Dotmatics

United Kingdom

4,155

0.7

PathFactory

Canada

3,649

0.6

Collingwood Insurance Group

United Kingdom

3,435

0.6

Vero Biotech

United States

3,366

0.6

GT Medical

United States

3,307

0.6

Educa Edtech

Spain

3,035

0.5

AccountsIQ

Ireland

2,477

0.4

Neurolens

United States

2,336

0.4

Alessa (Tier1 CRM)

Canada

2,083

0.4

Omlet

United Kingdom

2,039

0.4

OneTouch

United Kingdom

2,003

0.3

Agilico (DMC Canotec)

United Kingdom

1,734

0.3

Bomaki

Italy

1,469

0.3

Rephine

United Kingdom

1,289

0.2

Avalon

United Kingdom

1,234

0.2

Ambio Holdings

United States

1,211

0.2

Leader96

Bulgaria

748

0.1

Jollyes

United Kingdom

397

0.1

TDR Algeco/Scotsman

Europe

207

-

Total Direct - Investments/Co-investments


246,125

42.1

Total Portfolio


584,097

100.0

 

 

 

 

CT Private Equity Trust PLC

 

Statement of Comprehensive Income for the

year ended 31 December 2024

 

 


(Unaudited)

 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

25,144

25,144

Exchange gains

-

5,055

5,055

Investment income

3,270

-

3,270

Other income

961

-

961

Total income

4,231

30,199

34,430





Expenditure




Investment management fee - basic fee

(489)

(4,404)

(4,893)

Investment management fee - performance fee

-

-

-

Other expenses

(1,226)

-

(1,226)

Total expenditure

(1,715)

(4,404)

(6,119)





Profit before finance costs and taxation

2,516

25,795

28,311





Finance costs

(864)

(7,778)

(8,642)

 




Profit before taxation

1,652

18,017

19,669





Taxation

-

-

-





Profit for year/total comprehensive income

1,652

18,017

19,669

 




Return per Ordinary Share

2.30p

25.08p

27.38p

 

 



CT Private Equity Trust PLC

 

Statement of Comprehensive Income for the

year ended 31 December 2023

 

 


(Audited)

 


Revenue

£'000

Capital

£'000

Total

£'000

 

Income




Gains on investments held at fair value

-

25,226

25,226

Exchange gains

-

863

863

Investment income

2,703

-

2,703

Other income

689

-

689

Total income

3,392

26,089

29,481





Expenditure




Investment management fee - basic fee

(474)

(4,263)

(4,737)

Investment management fee - performance fee

-

(4,767)

(4,767)

Other expenses

(1,064)

-

(1,064)

Total expenditure

(1,538)

(9,030)

(10,568)





Profit before finance costs and taxation

1,854

17,059

18,913





Finance costs

(513)

(4,616)

(5,129)

 




Profit before taxation

1,341

12,443

13,784





Taxation

-

-

-





Profit for year/total comprehensive income

1,341

12,443

13,784

 




Return per Ordinary Share

1.84p

17.08p

18.92p

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CT Private Equity Trust PLC

 

Balance Sheet

 

 

 

As at 31 December 2024

(Unaudited)

As at 31 December 2023

(Audited)

 

 

£'000

£'000

Non-current assets

 


Investments at fair value through profit or loss

584,097

605,603


584,097

605,603

Current assets



Other receivables

1,110

841

Cash and cash equivalents

16,000

9,879


17,110

10,720

Current liabilities



Other payables

Interest-bearing bank loan

(3,859)

(43,944)

(8,121)

(97,109)

 

(47,803)

(105,230)

Net current liabilities

(30,693)

(94,510)

Total assets less current liabilities

553,404

511,093

 



Non-current liabilities



Interest-bearing bank loan

(48,575)

-

Net assets

504,829

511,093

 



Equity



Called-up ordinary share capital

739

739

Share premium account

2,527

2,527

Special distributable capital reserve

3,818

9,597

Special distributable revenue reserve

31,403

31,403

Capital redemption reserve

1,335

1,335

Capital reserve

465,007

465,492

Shareholders' funds

504,829

511,093




Net asset value per Ordinary Share

706.03p

702.50p

 



CT Private Equity Trust PLC

               

Statement of Changes in Equity

 

 

 

 

 

Share Capital

 

Share Premium Account

Special Distributable Capital Reserve

Special Distributable Revenue Reserve

 

Capital Redemption Reserve

 

 

Capital Reserve

 

 

Revenue Reserve

 

 

 

Total

 

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

For the year ended 31 December 2024 (unaudited)

 

 

 

 

 

 

 

Net assets at 1 January 2024

   739

2,527

9,597

31,403

1,335

465,492

-

511,093

Buyback of ordinary shares

 -

-

(5,779)

-

-

-

-

(5,779)

Profit for the year/total comprehensive income

-

  -

-

-

-

18,017

1,652

19,669

Dividends paid

-

-

-

-

-

(18,502)

(1,652)

(20,154)

 

 

 

 

 

 

 

 

 

Net assets at 31 December 2024

       739

2,527

3,818

31,403

1,335

465,007

-

504,829

 

 

 

 

 

 

 

 

 

For the year ended 31 December 2023 (audited)

 

 

 

 

 

 

 

Net assets at 1 January 2023

   739

2,527

10,026

31,403

1,335

471,645

-

517,675

Buyback of ordinary shares

 -

-

(429)

-

-

-

-

(429)

Profit for the year/total comprehensive income

-

  -

-

-

-

12,443

1,341

13,784

Dividends paid

-

-

-

-

-

(18,596)

(1,341)

(19,937)

 

 

 

 

 

 

 

 

 

Net assets at 31 December 2023

       739

2,527

9,597

31,403

1,335

465,492

-

511,093

 

 

 

 

 

 

 

 

 

 



CT Private Equity Trust PLC

 

Statement of Cash Flows

 

 

 

Year ended

31 December 2024

(Unaudited)

Year ended

31 December 2023

(Audited)

 

 

 

 

£000

£000

Operating activities



Profit before taxation

19,669

13,784

Adjustments for:

Gains on disposals of investments

 

(58,769)

 

(26,349)

Losses on account of fair value movement

33,625

1,123

Exchange differences

(5,055)

(863)

Interest Income

(961)

(689)

Interest received

937

668

Finance costs

8,642

5,129

Increase in other receivables

(266)

(8)

Decrease in other payables

(4,082)

(497)

 

Net cash outflow from operating activities

 

(6,260)

 

(7,702)

 



Investing activities



Purchases of investments

(58,712)

(110,784)

Sales of investments

105,362

58,964

 

Net cash inflow/(outflow) from investing activities

 

46,650

 

(51,820)

 



Financing activities



Drawdown of bank loans

2,182

59,023

Arrangement costs of loan facility

(1,468)

(27)

Interest paid

(8,209)

(3,995)

Equity dividends paid

(20,154)

(19,937)

Buyback of ordinary shares

(5,779)

(429)

 

Net cash (outflow)/inflow from financing activities

 

(33,428)

 

34,635

 

Net increase/(decrease) in cash and cash equivalents

 

6,962

 

(24,887)

Currency (losses)/gains

(841)

306

 

Net increase/(decrease) in cash and cash equivalents

 

6,121

 

(24,581)

Opening cash and cash equivalents

9,879

34,460

Closing cash and cash equivalents

16,000

9,879





 

 



 

 

Notes (unaudited)

 

1.              The unaudited financial results, which were approved by the Board on 27 March 2025, have been prepared in accordance with UK adopted international accounting standards. Where presentation guidance set out in the Statement of Recommended Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" ('SORP') issued by the Association of Investment Companies is consistent with the requirements of international accounting standards, the Directors have sought to prepare the financial statements on a basis compliant with the recommendations of the SORP.  The Directors have assessed Going Concern and consider it the appropriate basis for the figures presented in the announcement.

 

The accounting policies adopted are consistent with those of the previous financial year.

 

Standards issued but not yet effective

There are no standards or amendments to standards not yet effective that are relevant to the Company and should be disclosed.

 

2.             Returns per Ordinary Share are based on the following weighted average number of shares in issue during the year: 71,845,834 (2023: 72,838,637).

 

The net asset value per Ordinary Share is based on the following number of shares in issue at the year-end: 71,502,938 (2023: 72,752,938).

 

During the year ended 31 December 2024, the Company issued nil Ordinary Shares.  During the previous year ended 31 December 2023, the Company issued nil Ordinary Shares. During the year ended 31 December 2024, the Company bought back 1,250,000 Ordinary Shares to be held in treasury. During the previous year ended 31 December 2023, the Company bought back 92,000 Ordinary Shares to be held in treasury.

 

3.              The Board has proposed an interim dividend of 7.01 pence per Ordinary Share, payable on 30 April 2025 to those Shareholders on the register on 11 April 2025 with an ex-dividend date of 10 April 2025.

 

4.            This results announcement is based on the Company's unaudited financial statements for the year ended 31 December 2024 which have been prepared in accordance with UK adopted international accounting standards. 

5.            This announcement is not the Company's statutory accounts.  The full audited accounts for the year ended 31 December 2023, which were unqualified and had no emphasis of matters, have been lodged with the Registrar of Companies.  The statutory accounts for the year to 31 December 2024 (on which the audit report has not yet been signed) will be delivered to the Registrar of Companies following the Company's Annual General Meeting which will be held at Cannon Place, 78 Cannon Street, London, EC4N 6AG on 29 May 2025 at 13.00.

 

6.             The Annual Report and Accounts for the year will be sent to Shareholders and will be available for inspection at the Company's registered office, Quartermile 4, 7a Nightingale Way, Edinburgh, EH3 9EG and the Company's website www.ctprivateequitytrust.com. The Company intends to issue a subsequent annual financial report announcement.

 

 

  For more information, please contact:

 

Hamish Mair (Investment Manager)

0131 573 8300

Scott McEllen (Company Secretary)

0131 573 8300

hamish.mair@columbiathreadneedle.com  /

scott.mcellen@columbiathreadneedle.com

 

 

 

 

 

 

Appendix: Alternative Performance Measures

 

The Company uses the following Alternative Performance Measures ('APMs'):

 

Discount (or premium) - If the share price of an Investment Trust is less than its Net Asset Value per share, the shares are trading at a discount.  If the share price is greater than the Net Asset Value per share, the shares are trading at a premium.

 



31 December 2024

31 December 2023

Net Asset Value per share (pence)

(a)

706.03

702.50

Share price per share (pence)

(b)

488.00

468.00

Discount (c=(b-a)/a)

(c)

30.9%

33.4%

 

Dividend Yield - The dividends declared for the year divided by the share price at the year end. 

 

Gearing - This is the ratio of the borrowings less cash of the Company to its total assets less current liabilities (excluding borrowings and cash).  Borrowings may include: preference shares; debentures; overdrafts and short and long-term loans from banks; and derivative contracts.  If the Company has cash assets, these may be assumed either to net off against borrowings, giving a "net" or "effective" gearing percentage, or to be used to buy investments, giving a "gross" or "fully invested" gearing figure.  Where cash assets exceed borrowings, the Company is described as having "net cash".

 



31 December 2024

31 December 2023



£'000

£'000

Borrowings less cash

(a)

76,519

87,230

Total assets less current liabilities (excluding borrowings and cash)

(b)

581,348

598,323

Gearing (c=a/b)

(c)

13.2%

14.6%

 

Ongoing Charges - All operating costs expected to be incurred in future and that are payable by the Company expressed as a proportion of the average Net Assets of the Company over the reporting year.  The costs of buying and selling investments are excluded, as are interest costs, taxation, performance fees, non-recurring costs and the costs of buying back or issuing Ordinary Shares.  Ongoing charges of the Company's underlying investments are also excluded.

 


Year to

31 December 2024

Year to

31 December 2023

Ongoing charges (£'000)

6,119

5,801

Ongoing charges as a percentage of average assets:

1.2%

1.1%

Ongoing charges (including performance fees) (£'000)

6,119

10,568

Ongoing charges (including performance fees) as a percentage of average net assets:

 

1.2%

 

2.1%

Average net assets (£'000)

499,457

508,718

 

Total Return - The return to Shareholders calculated on a per share basis by adding dividends paid in the period to the increase or decrease in the Share Price or NAV. The dividends are assumed to have been reinvested in the form of Ordinary Shares or Net Assets.

 


Year to 31 December 2024

Year to 31 December 2023

NAV per share at start of year (pence)

702.50

710.65

NAV per share at end of year (pence)

706.03

702.50

Change in year

+0.5%

-1.1%

Impact of dividend reinvestments

+4.1%

+3.9%

Total NAV return for the year

+4.6%

+2.8%

 

                         

 


Year to 31 December 2024

Year to 31 December 2023

Share price per share at start of year (pence)

468.00

423.00

Share price per share at end of year (pence)

488.00

468.00

Change in year

+4.3%

+10.6%

Impact of dividend reinvestments

+6.6%

+7.0%

Total share price return for the year

+10.9%

+17.6%

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR VDLFLEXLZBBD